State of New Jersey Common Pension Fund D boosted its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 38.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 42,539 shares of the company's stock after acquiring an additional 11,782 shares during the period. State of New Jersey Common Pension Fund D owned about 0.08% of LivaNova worth $2,235,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of LIVN. Arizona State Retirement System grew its stake in shares of LivaNova by 2.0% in the second quarter. Arizona State Retirement System now owns 15,104 shares of the company's stock worth $828,000 after purchasing an additional 299 shares in the last quarter. Atria Investments Inc boosted its holdings in shares of LivaNova by 6.2% in the third quarter. Atria Investments Inc now owns 5,653 shares of the company's stock valued at $297,000 after acquiring an additional 331 shares in the last quarter. Fifth Third Bancorp increased its stake in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after acquiring an additional 332 shares during the period. Hexagon Capital Partners LLC raised its holdings in LivaNova by 117.8% during the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after purchasing an additional 370 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in LivaNova by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock worth $328,000 after purchasing an additional 425 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on LIVN shares. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Stifel Nicolaus increased their price target on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Thursday, July 25th. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday, October 4th. They set a "buy" rating and a $65.00 price objective for the company. Baird R W raised shares of LivaNova from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, Needham & Company LLC restated a "buy" rating and issued a $75.00 price target on shares of LivaNova in a research report on Tuesday. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $69.17.
Read Our Latest Stock Report on LIVN
LivaNova Stock Performance
Shares of NASDAQ:LIVN traded down $0.85 during trading on Friday, hitting $51.47. 111,652 shares of the stock were exchanged, compared to its average volume of 617,174. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of 123.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company's fifty day simple moving average is $51.67 and its 200-day simple moving average is $52.98.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Articles
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
